Fianlimab vs Relatlimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Melanoma

Shared mechanism: LAG-3 · full Melanoma pipeline

Fianlimab

Developed by Regeneron Pharmaceuticals

Phase 3 in Melanomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2027 · NCT05608291 (registry estimate)

No aligned efficacy figure on record for this race.

Relatlimab

Marketed by Bristol-Myers Squibb and partners

Approved in Melanomamonoclonal antibody
Reliable signal

NCT03470922 · Phase 2/3 · active, not recruiting

This was a randomized, double-blind trial in 714 people with previously untreated advanced melanoma, comparing relatlimab plus nivolumab with nivolumab alone, and its primary endpoint, progression-free survival assessed by blinded central review, was met (hazard ratio 0.75, p=0.0055). A power calculation for this endpoint was reported, and 714 participants were randomized against a planned 700.

Next expected readout: November 2026 · NCT06712927 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62) (met)

Result source: NCT03470922

Results for Melanoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Fianlimab: no structured comparison results are available for Melanoma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Relatlimab
Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62) NCT03470922 · Phase 2/3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fianlimab's landscape · Relatlimab's landscape